What Is the Future of Immunotherapy in Ovarian Cancer

[1]  J. Gulley.  Therapeutic vaccines , 2013, Human vaccines & immunotherapeutics.

[2]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[3]  C. Morrison,et al.  Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients , 2012, Proceedings of the National Academy of Sciences.

[4]  G. Coukos,et al.  Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Tatsuhiko Tsunoda,et al.  High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway , 2012, Clinical Cancer Research.

[6]  G. Coukos,et al.  In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). , 2011, Cancer research.

[7]  J. Kelley,et al.  A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer , 2010, Cancer Immunology, Immunotherapy.

[8]  Yun Ji,et al.  Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity , 2009, Proceedings of the National Academy of Sciences.

[9]  Bruce R. Blazar,et al.  Engineering lymphocyte subsets: tools, trials and tribulations , 2009, Nature Reviews Immunology.

[10]  C. Ahonen,et al.  In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. , 2009, Cancer research.

[11]  R. Vonderheide,et al.  Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells , 2009, Annals of the New York Academy of Sciences.

[12]  C. Mackall,et al.  Modulating T‐cell homeostasis with IL‐7: preclinical and clinical studies , 2009, Journal of internal medicine.

[13]  G. Mor,et al.  KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells , 2009, Journal of Translational Medicine.

[14]  G. Coukos,et al.  Endothelin B Receptor, a New Target in Cancer Immune Therapy , 2009, Clinical Cancer Research.

[15]  P. Gimotty,et al.  Intraepithelial T cells and tumor proliferation , 2009, Cancer.

[16]  G. Shurin,et al.  Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism1 , 2009, The Journal of Immunology.

[17]  Upendra K. Kar,et al.  IL-7 Promotes CXCR3 Ligand-Dependent T Cell Antitumor Reactivity in Lung Cancer1 , 2009, The Journal of Immunology.

[18]  James L Riley,et al.  Human T regulatory cell therapy: take a billion or so and call me in the morning. , 2009, Immunity.

[19]  T. O'brien,et al.  Cellular immunotherapy for ovarian cancer , 2009, Expert opinion on biological therapy.

[20]  R. Noelle,et al.  Molecular mechanism and function of CD40/CD40L engagement in the immune system , 2009, Immunological reviews.

[21]  S. Rosenberg,et al.  Adoptive cell therapy for the treatment of patients with metastatic melanoma. , 2009, Current opinion in immunology.

[22]  I. Pastan,et al.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.

[23]  Matt van de Rijn,et al.  Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss , 2009, Modern Pathology.

[24]  S. Rosenberg,et al.  Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells , 2009, Clinical Cancer Research.

[25]  E. Small,et al.  Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Xiong,et al.  Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. , 2008, Clinical immunology.

[27]  M. Neller,et al.  Antigens for cancer immunotherapy. , 2008, Seminars in immunology.

[28]  G. Coukos,et al.  Distinct Effects of IL-18 on the Engraftment and Function of Human Effector CD8+ T Cells and Regulatory T Cells , 2008, PloS one.

[29]  A. Alshamsan,et al.  Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. , 2008, Vaccine.

[30]  R. Perret,et al.  Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? , 2008, Tissue antigens.

[31]  C. Leichman,et al.  Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Rosenberg,et al.  Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. , 2008, Human gene therapy.

[33]  G. Coukos,et al.  Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation , 2008, Cancer biology & therapy.

[34]  J. Ledermann,et al.  Oxidation of Ovarian Epithelial Cancer Cells by Hypochlorous Acid Enhances Immunogenicity and Stimulates T Cells that Recognize Autologous Primary Tumor , 2008, Clinical Cancer Research.

[35]  S. Adams,et al.  Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant1 , 2008, The Journal of Immunology.

[36]  A. Scheffold,et al.  IL‐2 induces in vivo suppression by CD4+CD25+Foxp3+ regulatory T cells , 2008, European journal of immunology.

[37]  J. Kirkwood,et al.  A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer , 2008, Clinical Cancer Research.

[38]  R. Berger,et al.  Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies , 2008, Clinical Cancer Research.

[39]  S. Steinberg,et al.  Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma , 2008, Clinical Cancer Research.

[40]  Bent K. Jakobsen,et al.  Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions , 2008, The Journal of Immunology.

[41]  Rochelle L. Garcia,et al.  Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. , 2008, Gynecologic oncology.

[42]  C. Slingluff,et al.  A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer , 2008, Journal of immunotherapy.

[43]  D. Alberts,et al.  Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. , 2008, Gynecologic oncology.

[44]  G. Coukos,et al.  Whole tumor antigen vaccination using dendritic cells: Comparison of RNA electroporation and pulsing with UV-irradiated tumor cells , 2008, Journal of Translational Medicine.

[45]  B. Redman,et al.  Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R. Roden,et al.  Antigen‐specific immunotherapy of cervical and ovarian cancer , 2008, Immunological reviews.

[47]  Sylvain Julien,et al.  Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor1 , 2008, The Journal of Immunology.

[48]  Xiefu Zhang,et al.  [Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma]. , 2008, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[49]  D. Neuberg,et al.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.

[50]  G. Coukos,et al.  Immunotherapy opportunities in ovarian cancer , 2008, Expert review of anticancer therapy.

[51]  P. Sabbatini,et al.  REVIEW ARTICLE: Harnessing the Immune System for Ovarian Cancer Therapy , 2007, American journal of reproductive immunology.

[52]  J. Leonard,et al.  Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma , 2007, Clinical Cancer Research.

[53]  G. Zhu,et al.  Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. , 2007, Cancer research.

[54]  J. Levêque,et al.  Effects of CD40 binding on ovarian carcinoma cell growth and cytokine production in vitro , 2007, Clinical and experimental immunology.

[55]  K. Odunsi,et al.  Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[56]  P. Sabbatini,et al.  Immunologic approaches to ovarian cancer treatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  E. Jaffee,et al.  A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism , 2007, Clinical Cancer Research.

[58]  C. June,et al.  Adoptive T cell therapy for cancer in the clinic. , 2007, The Journal of clinical investigation.

[59]  Prim B. Singh,et al.  Interleukin-21: a new modulator of immunity, infection, and cancer. , 2007, Cytokine & growth factor reviews.

[60]  T. Waldmann.  Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma , 2007, Oncogene.

[61]  C. June,et al.  Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[62]  A. Mackensen,et al.  Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion , 2007, Cancer Immunology, Immunotherapy.

[63]  B. Chauffert,et al.  Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.

[64]  B. Melichar,et al.  Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. , 2007, Gynecologic oncology.

[65]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[66]  P. Wallace,et al.  Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells , 2007, Journal of Translational Medicine.

[67]  H. Koenen,et al.  Following Anti‐CD25 Treatment, A Functional CD4+CD25+ Regulatory T‐Cell Pool Is Present in Renal Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[68]  S. Rosenberg,et al.  Persistence of Tumor Infiltrating Lymphocytes in Adoptive Immunotherapy Correlates With Telomere Length , 2007, Journal of immunotherapy.

[69]  D. Speiser,et al.  Human Effector CD8+ T Lymphocytes Express TLR3 as a Functional Coreceptor1 , 2006, The Journal of Immunology.

[70]  V. Quillien,et al.  Immunologic and Clinical Effects of Injecting Mature Peptide-Loaded Dendritic Cells by Intralymphatic and Intranodal Routes in Metastatic Melanoma Patients , 2006, Clinical Cancer Research.

[71]  P. Conti,et al.  IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances. , 2006, Journal of experimental & clinical cancer research : CR.

[72]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[73]  A. Bossler,et al.  Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma , 2006, Journal of immunotherapy.

[74]  A. Ribas.  Update on immunotherapy for melanoma. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[75]  Michael Atkins,et al.  Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer , 2006, Clinical Cancer Research.

[76]  C. Figdor,et al.  Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. , 2006, Cancer research.

[77]  G. Coukos,et al.  Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity , 2006, Cancer biology & therapy.

[78]  S. Rosenberg,et al.  Modulation by IL-2 of CD70 and CD27 Expression on CD8+ T Cells: Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy1 , 2006, The Journal of Immunology.

[79]  R. Chen,et al.  TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. , 2006, Cancer research.

[80]  N. Urban,et al.  Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[82]  M. Levings,et al.  Human CD4+ T Cells Express TLR5 and Its Ligand Flagellin Enhances the Suppressive Capacity and Expression of FOXP3 in CD4+CD25+ T Regulatory Cells1 , 2005, The Journal of Immunology.

[83]  S. Rosenberg,et al.  Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1 , 2005, The Journal of Immunology.

[84]  H. Tajiri,et al.  Dendritic Cells Fused with Allogeneic Colorectal Cancer Cell Line Present Multiple Colorectal Cancer–Specific Antigens and Induce Antitumor Immunity against Autologous Tumor Cells , 2005, Clinical Cancer Research.

[85]  S. Rosenberg,et al.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells , 2005, The Journal of experimental medicine.

[86]  Weiyi Peng,et al.  Toll-Like Receptor 8-Mediated Reversal of CD4+ Regulatory T Cell Function , 2005, Science.

[87]  V. Schirrmacher.  Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory , 2005, Cancer Immunology, Immunotherapy.

[88]  G. Coukos,et al.  T regulatory cell depletion can boost DC-based vaccines , 2005 .

[89]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[91]  F. Ronchese,et al.  Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells1 , 2005, The Journal of Immunology.

[92]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[93]  K. Knutson,et al.  Humoral Epitope-Spreading Following Immunization with a HER-2/neu Peptide Based Vaccine in Cancer Patients , 2004, Journal of Clinical Immunology.

[94]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[95]  G. Hall,et al.  Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study , 2004, British Journal of Cancer.

[96]  E. Borden,et al.  Phase 2 Trial of Interferon-Beta as Second-Line Treatment of Ovarian Cancer, Fallopian Tube Cancer, or Primary Carcinoma of the Peritoneum , 2004, Oncology.

[97]  Michael T. Lotze,et al.  Inflammation and necrosis promote tumour growth , 2004, Nature Reviews Immunology.

[98]  R. Kreienberg,et al.  Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125 , 2004, Clinical Cancer Research.

[99]  K. Ushijima,et al.  Vaccination with Predesignated or Evidence-Based Peptides for Patients with Recurrent Gynecologic Cancers , 2004, Journal of immunotherapy.

[100]  W. Sterry,et al.  The use of Toll‐like receptor‐7 agonist in the treatment of basal cell carcinoma: an overview , 2003, The British journal of dermatology.

[101]  B. Melichar,et al.  rIFN-γ-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition , 2003, Journal of Translational Medicine.

[102]  Z. Eshhar,et al.  Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. , 2003, Cancer research.

[103]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[104]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[105]  G. Coukos,et al.  TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[106]  J. Wahlfors,et al.  CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[107]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[108]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[109]  J. Dutcher,et al.  Managing toxicities of high-dose interleukin-2. , 2002, Oncology.

[110]  Drew M. Pardoll,et al.  Vaccines: Spinning molecular immunology into successful immunotherapy , 2002, Nature Reviews Immunology.

[111]  J. Crocker,et al.  CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion , 2002, Molecular pathology : MP.

[112]  T. Bauknecht,et al.  Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial , 2002, Cancer Immunology, Immunotherapy.

[113]  B. Hylander,et al.  Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. , 2001, Cancer research.

[114]  P. Marrack,et al.  CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in the absence of tumor-antigen vaccination , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[115]  G. Coukos,et al.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.

[116]  S. Rosenberg,et al.  Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. , 2000, Human gene therapy.

[117]  G. Parham,et al.  Induction of Ovarian Tumor‐Specific CD8+ Cytotoxic T Lymphocytes by Acid‐Eluted Peptide‐Pulsed Autologous Dendritic Cells , 2000, Obstetrics and gynecology.

[118]  S. Cannistra,et al.  Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity1 , 2000, The Journal of Immunology.

[119]  J. Metcalf,et al.  Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. , 2000, Blood.

[120]  B. Melichar,et al.  Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[121]  T. Di Pucchio,et al.  Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. , 2000, Blood.

[122]  H. Hausmaninger,et al.  Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial , 2000, British Journal of Cancer.

[123]  S. Egawa,et al.  Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. , 2000, Cancer research.

[124]  J. Berek,et al.  Intraperitoneal Interferon-α in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study , 1999 .

[125]  K. Nishioka,et al.  Clonal expansion of T cells that are specific for autologous ovarian tumor among tumor-infiltrating T cells in humans. , 1999, Gynecologic oncology.

[126]  T. Waldmann,et al.  Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[127]  A. Kudelka,et al.  Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides , 1998, Annals of Surgical Oncology.

[128]  J. D. White,et al.  Reduction in HTLV‐I proviral load and spontaneous lymphoproliferation in HTLV‐I–associated myelopathy/tropical spastic paraparesis patients treated with humanized anti‐tac , 1998, Annals of neurology.

[129]  Loise M. Francisco,et al.  Tumor-specific killer cells in paraneoplastic cerebellar degeneration , 1998, Nature Medicine.

[130]  S. Light,et al.  Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. , 1998, Transplantation proceedings.

[131]  S. Rosenberg,et al.  A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a human ovarian cancer antigen , 1998, Nature Medicine.

[132]  J. Kirkwood,et al.  Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  R. Freedman,et al.  HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. , 1996, Cellular immunology.

[134]  M. Roth,et al.  Interleukin-7 gene transfer in non-small-cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances antitumor reactivity. , 1996, Cancer gene therapy.

[135]  S. Rosenberg,et al.  Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. , 1996, The cancer journal from Scientific American.

[136]  S. Richards,et al.  UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response , 1995, The Lancet.

[137]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.

[138]  Kenichi Tanaka,et al.  Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[139]  T. Eberlein,et al.  Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[140]  E. Atkinson,et al.  Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[141]  R. Freedman,et al.  Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. , 1993, Lymphokine and cytokine research.

[142]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[143]  W. DenOtter,et al.  Concepts in immunotherapy of cancer: introduction. , 1991 .

[144]  Kenichi Tanaka,et al.  Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. , 1991, Cancer research.

[145]  M. Katsuki,et al.  Anomalies in transgenic mice carrying the human interleukin-2 gene. , 1990, The Tokai journal of experimental and clinical medicine.

[146]  J. Wharton,et al.  T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production. , 1990, Anticancer research.

[147]  J. Berek,et al.  A phase I–II trial of intraperitoneal cisplatin and α-lnterferon in patients with persistent epithelial ovarian cancer , 1990 .

[148]  Z. Eshhar,et al.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[149]  H. Heimpel,et al.  A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia , 1989, Blut.

[150]  J. Rinehart,et al.  Phase I/II Trial of Interferon-β-Serine in Patients with Renal Cell Carcinoma; Immunological and Biological Effects , 1987 .

[151]  P. Bunn,et al.  Alpha interferon treatment of low-grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia. , 1986, Seminars in oncology.

[152]  J. Kirkwood,et al.  Melanoma: therapeutic options with recombinant interferons. , 1985, Seminars in oncology.

[153]  J. Quesada,et al.  Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  J. Kirkwood,et al.  Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. , 1985, Annals of internal medicine.

[155]  P. Hersey,et al.  Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. , 1985, British Journal of Cancer.

[156]  D. Ahmann,et al.  Phase II study of recombinant leukocyte a interferon (rIFN‐αA) in disseminated malignant melanoma , 1984, Cancer.

[157]  J. O'fallon,et al.  Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  A. Iasonos,et al.  Consolidation strategies in ovarian cancer: observations for future clinical trials. , 2010, Gynecologic oncology.

[159]  R. Schulick,et al.  Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination , 2009, Cancer Immunology, Immunotherapy.

[160]  P. Gimotty,et al.  Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy , 2008, Nature Medicine.

[161]  L. Capelle,et al.  Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. , 2006, Neuro-oncology.

[162]  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use , 2006 .

[163]  S. Rosenberg,et al.  Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. , 2005, Blood.

[164]  E. Halapi,et al.  Restricted T cell receptor V-β and J-β usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas , 2005, Cancer Immunology, Immunotherapy.

[165]  M. Bhat,et al.  Differential expression of CD40 and CD95 in ovarian carcinoma. , 2004, European Journal of Gynaecological Oncology.

[166]  F. Balkwill,et al.  The Anti-proliferative Activity of Interferon-γ on Ovarian Cancer: In Vitro and in Vivo , 2003 .

[167]  Michel Sadelain,et al.  Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.

[168]  K. Karjalainen,et al.  Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors. , 1998, Advances in immunology.

[169]  P. Canal,et al.  Modulation of cisplatin cytotoxicity by human recombinant interferon-γ in human ovarian cancer cell lines , 1994 .

[170]  T. Eberlein,et al.  T-cell recognition of ovarian cancer. , 1993, Surgery.

[171]  R. Freedman,et al.  Immunological effects of tumor vaccines: II. T cell responses directed against cellular antigens in the viral oncolysates. , 1990, In Vivo.

[172]  H. Rübben,et al.  Long-term interferon treatment in metastatic renal cell carcinoma. , 1989, European urology.

[173]  D. Berd,et al.  Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. , 1988, Cancer investigation.